Published • loading... • Updated
White House to announce new drug pricing deals with biotechs, Bloomberg News reports
The voluntary deals would extend Medicaid drug discounts to more biotech firms as the administration says pricing agreements could save $64.3 billion over 10 years.
- On Wednesday, Bloomberg News reported that President Donald Trump's administration plans to announce new drug-pricing agreements with midsize biotech companies on Monday, aligning state Medicaid prices with international costs.
- To date, the Trump administration has reached voluntary agreements with 17 pharmaceutical companies, including Pfizer, Eli Lilly, and Amgen, to slash medicine prices for Medicaid and cash payers.
- In May, the administration said the pricing deals are expected to generate $64.3 billion in federal and state savings over the next 10 years.
- Pressuring drugmakers to match international prices, Trump secured price reductions for GLP-1 drugs while expanding Medicare coverage for obesity treatments.
- Details regarding which specific drugmakers are involved remain unclear, and Reuters could not immediately verify the report regarding the upcoming announcement.
Insights by Ground AI
6 Articles
6 Articles
White House to announce new drug pricing deals with biotechs, Bloomberg News reports
U.S. President Donald Trump's administration is planning to announce a new round of drug-pricing agreements with midsize biotech companies on Monday, Bloomberg News reported on Wednesday, citing people familiar with the matter.
·London, United Kingdom
Read Full Article
Coverage Details
Total News Sources6
Leaning Left0Leaning Right1Center4Last UpdatedBias Distribution80% Center
Bias Distribution
- 80% of the sources are Center
80% Center
C 80%
R 20%
Factuality
To view factuality data please Upgrade to Premium
